Dectrekumab/VAK-694

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDectrekumab/VAK-694
Drug Alias NameVAK-694/DectrekumabQBX-258
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-13 inhibitorsInterleukin-4 inhibitors
TargetsInterleukin-4Interleukin-13
Therapy Area/IndicationsLymphedemaAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes VAK-694Dectrekumab
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsLymphedemaAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A